Natera, Inc.(NTRA)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions.
In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services.
The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma.
The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Natera, Inc. (NTRA) over the last 3 months consists of 193 total transactions. Among these, company executives and board members conducted 193 buys (totaling 2,252,917 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 2,252,917 shares, reflecting net buying interest with an estimated net acquisitions value of $478.24M.
193 insider transactions found. Showing 10 of 193 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| SHEENA JONATHAN | Director | 6,000 | $1.95 | Aug 10, 2026 |
| RABINOWITZ MATTHEW | Officer and Director | 2,000 | $0.64 | Aug 7, 2026 |
| SHEENA JONATHAN | Director | 9,150 | $2.89 | Aug 7, 2026 |
| BROPHY MICHAEL BURKES | Chief Financial Officer | 795 | $0.22 | Aug 4, 2026 |
| RABINOWITZ MATTHEW | Officer and Director | 731 | $0.20 | Aug 3, 2026 |
| SHEENA JONATHAN | Director | 109 | $29211.00 | Aug 3, 2026 |
| FESKO JOHN | President | 295 | $0.08 | Aug 3, 2026 |
| MOSHKEVICH SOLOMON | Officer | 3,410 | $0.91 | Aug 3, 2026 |
| CHAPMAN STEVEN LEONARD | Chief Executive Officer | 3,076 | $0.82 | Aug 3, 2026 |
| RABINOWITZ DANIEL A | Officer | 334 | $0.09 | Aug 3, 2026 |
Explore More Analysis for NTRA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.